• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Letter: the addition of an immunosuppressant in patients with unsatisfactory response to vedolizumab-Authors' reply.

作者信息

Strik A S, D'Haens G R

机构信息

Department of Gastroenterology, Academic Medical Centre, Amsterdam, The Netherlands.

出版信息

Aliment Pharmacol Ther. 2018 Apr;47(7):1041-1042. doi: 10.1111/apt.14570.

DOI:10.1111/apt.14570
PMID:29512914
Abstract
摘要

相似文献

1
Letter: the addition of an immunosuppressant in patients with unsatisfactory response to vedolizumab-Authors' reply.
Aliment Pharmacol Ther. 2018 Apr;47(7):1041-1042. doi: 10.1111/apt.14570.
2
Letter: the addition of an immunosuppressant in patients with unsatisfactory response to vedolizumab.信件：对维多珠单抗反应不佳的患者加用免疫抑制剂。
Aliment Pharmacol Ther. 2018 Apr;47(7):1040-1041. doi: 10.1111/apt.14541.
3
Editorial: biologic therapies for primary sclerosing cholangitis-more disappointment than promise? Authors' reply.
Aliment Pharmacol Ther. 2018 Sep;48(5):578-579. doi: 10.1111/apt.14907.
4
Letter: comparative safety and efficacy of infliximab vs. adalimumab in Crohn's disease - should one consider disease location? Authors' reply.
Aliment Pharmacol Ther. 2016 Oct;44(7):772-3. doi: 10.1111/apt.13768.
5
Letter: can addition of an immunomodulator really reverse antibody formation and loss of response in patients treated with adalimumab?信函：对于使用阿达木单抗治疗的患者，添加一种免疫调节剂真的能逆转抗体形成和反应丧失吗？
Aliment Pharmacol Ther. 2017 Mar;45(5):759-760. doi: 10.1111/apt.13921.
6
Letter: vedolizumab for autoimmune liver disease associated inflammatory bowel disease-Authors' reply.信函：维多珠单抗用于自身免疫性肝病相关的炎症性肠病——作者回复
Aliment Pharmacol Ther. 2018 May;47(10):1423-1424. doi: 10.1111/apt.14638.
7
Letter: vedolizumab drug levels in cord and maternal blood in women with inflammatory bowel disease-authors' reply.
Aliment Pharmacol Ther. 2018 Aug;48(3):388-389. doi: 10.1111/apt.14855.
8
Levels of drug and antidrug antibodies are associated with outcome of interventions after loss of response to infliximab or adalimumab.药物和抗体的水平与英夫利昔单抗或阿达木单抗治疗应答失败后的干预效果相关。
Clin Gastroenterol Hepatol. 2015 Mar;13(3):522-530.e2. doi: 10.1016/j.cgh.2014.07.029. Epub 2014 Jul 25.
9
Novel biologics in inflammatory bowel disease.炎症性肠病中的新型生物制剂。
Gastroenterol Clin North Am. 2004 Jun;33(2):251-69, ix. doi: 10.1016/j.gtc.2004.02.007.
10
Molecular mechanisms of action of anti-TNF-α agents - Comparison among therapeutic TNF-α antagonists.抗 TNF-α 药物的作用机制分子 - 治疗性 TNF-α 拮抗剂的比较。
Cytokine. 2018 Jan;101:56-63. doi: 10.1016/j.cyto.2016.08.014. Epub 2016 Aug 24.